Product Characteristics and Pharmacological Profile of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in the Phase II Registrational ZUMA-2 Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 50 条
  • [21] PATIENT REPORTED OUTCOMES AMONG KTE-X19 CAR T TREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)
    Kersten, Jose M.
    Munoz, J.
    Milpied, N.
    Maglinte, G.
    Crawford, S.
    Solem, C.
    Rao, A., V
    Wang, M.
    VALUE IN HEALTH, 2020, 23 : S479 - S479
  • [22] ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
    Wang, M.
    Locke, F. L.
    Siddiqi, T.
    Castro, J.
    Shah, B.
    Lee, H.
    Budde, L. E.
    Choi, M.
    Anasetti, C.
    Champlin, R.
    Forman, S.
    Kipps, T.
    Bot, A.
    Rossi, J. M.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J.
    Go, W. Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
  • [24] Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
    Wayne, Alan S.
    Van Huynh, Van
    Hijiya, Nobuko
    Rouce, Rayne H.
    Brown, Patrick A.
    Krueger, Joerg
    Kitko, Carrie L.
    Dela Ziga, Edward
    Hermiston, Michelle L.
    Richards, Michael K.
    Baruchel, Andre
    Schuberth, Petra C.
    Rossi, John
    Zhou, Lang
    Goyal, Lovely
    Jain, Rajul
    Vezan, Remus
    Masouleh, Behzad Kharabi
    Lee, Daniel W.
    HAEMATOLOGICA, 2023, 108 (03) : 747 - 760
  • [25] ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (RR) chronic lymph ocytic leukemia (CLL).
    Flinn, Ian
    Marris, Michael
    Wierda, William G.
    Coutre, Steven
    Pagel, John M.
    Byrd, John C.
    Goyal, Lovely
    Goodman, Krista
    Zheng, Yan
    Milletti, Francesca
    Murugappan, Swaminathan
    Brown, Jennifer R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group
    Herbaux, Charles
    Bret, Caroline
    Di Blasi, Roberta
    Bachy, Emmanuel
    Beauvais, David
    Gat, Elodie
    Gastinne, Thomas
    Broussais, Florence
    Cartron, Guillaume
    Cuffel, Alexis
    Ysebaert, Loic
    Roussel, Mikael
    Bouabdallah, Krimo
    Guy, Julien
    Campidelli, Arnaud
    Van Laethem, Francois
    Casasnovas, Rene-Olivier
    Dulery, Remy
    Morschhauser, Franck
    Caillat-Zucman, Sophie
    Houot, Roch
    Le Gouill, Steven
    BLOOD, 2021, 138
  • [27] HEALTH-RELATED QUALITY OF LIFE AMONG REFRACTORY/RELAPSED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH KTE-X19: PHASE 2 RESULTS FROM ZUMA-3 TRIAL
    Shah, B. D.
    Solem, C.
    Feng, C.
    Maglinte, G. A.
    Wang, W. J.
    Shen, T.
    Masouleh, B. K.
    Houot, R.
    VALUE IN HEALTH, 2022, 25 (01) : S238 - S238
  • [28] KTE-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study From the DESCAR-T Registry and LYSA Group
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 15 - 16
  • [29] Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial
    Furtado, Michelle
    Dyer, Martin J. S.
    Johnson, Rod
    Berrow, Margie
    Rule, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) : 575 - 578
  • [30] Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Jimenez-Ubieto, Ana
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Nunes, Ana
    Reitan, John
    Wade, Sally W.
    Salles, Gilles
    LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 14 - 25
12345